Lynn is a biotech entrepreneur and the founder of STALICLA. Driven by her lifelong involvement with the autism patient and research community, she codeveloped the Databased Endophenotyping Patient Identification model to kick-start systems biology-based drug development in ASD. Lynn has extensive experience in Business Development and has previously worked for the World Economic Forum, a leading Swiss venture capital firm, and startup accelerators in the lemanic area. She has also spent 5 years at the Faculty of Medicine at the University of Geneva. Lynn Durham holds a master degree in political sciences and economic history and another in corporate communication. Lynn also pursued a post-graduate degree in Drug Discovery and Clinical Development with a focus in pharmacology.
Benjamin is the Global Head of Overlay Management at Edmond de Rothschild Asset Management Suisse and a member of the enlarged executive committee of EDRAM. He holds a Post-Graduate Master’s Degree in Engineering, IT and Mathematics and a Masters in Finance from ESSEC business school.
Hugo Ferreira is Director of Huniel Conseil S.A.(created in 2014) in Geneva. He joined in 1991 La Compagnie Benjamin de Rothschild S.A.as Deputy General Manager until end of 2013. He has an extensive experience in finance (finance director, treasurer, structuring loan department, corporate finance), working for well-known institutions such as Nestlé (Switzerland and the USA), Citicorp Investment Bank (New York), as well as the Group Tradition. He is a non-executive director of Cobepa and several Private Equity funds.
Hugo is a commercial engineer from the Solvay School (Université Libre de Bruxelles) and holds a MBA from Columbia University (New York).
Jacques Bonvin is Partner at Tavernier Tschanz. After training mainly in international commercial arbitration and litigation, Jacques Bonvin has specialized over the last twenty years, and is now active in corporate law, international mergers and acquisitions and corporate finance, including private equity and venture capital, with a special emphasis on the technology and biotechnology sector. Jacques Bonvin regularly advises board of directors on corporate governance and strategic issues.